Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr1.04 DKK
Change Today 0.00 / 0.00%
Volume 692.4K
VELO On Other Exchanges
Symbol
Exchange
Copenhagen
OTC US
Frankfurt
As of 6:57 AM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

veloxis pharmaceuticals a/s (VELO) Snapshot

Open
kr1.04
Previous Close
kr1.04
Day High
kr1.05
Day Low
kr1.03
52 Week High
09/30/14 - kr2.10
52 Week Low
04/30/15 - kr0.75
Market Cap
1.7B
Average Volume 10 Days
1.6M
EPS TTM
kr-0.03
Shares Outstanding
1.7B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VELOXIS PHARMACEUTICALS A/S (VELO)

Related News

No related news articles were found.

veloxis pharmaceuticals a/s (VELO) Related Businessweek News

No Related Businessweek News Found

veloxis pharmaceuticals a/s (VELO) Details

Veloxis Pharmaceuticals A/S operates as a specialty pharmaceutical company. The company’s proprietary technology, MeltDose is designed to enhance the absorption and bioavailability of select orally administered drugs. Its lead product candidate is Envarsus, a once-daily dosage tablet version of tacrolimus for the treatment of kidney transplant patients. The company was formerly known as LifeCycle Pharma A/S and changed its name to Veloxis Pharmaceuticals A/S in July 2011. Veloxis Pharmaceuticals A/S is headquartered in Hørsholm, Denmark.

30 Employees
Last Reported Date: 08/26/15

veloxis pharmaceuticals a/s (VELO) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

veloxis pharmaceuticals a/s (VELO) Key Developments

Veloxis Pharmaceuticals A/S Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015; Provides Earnings Guidance for the Year 2015

Veloxis Pharmaceuticals A/S reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported revenue of DKK 5,292,000 compared to DKK 12,206,000 a year ago. Operating loss was DKK 35,914,000 against DKK 35,850,000 a year ago. Loss before tax was DKK 40,587,000 compared to DKK 34,622,000 a year ago. Net loss for the period was DKK 39,109,000 compared to DKK 33,127,000 a year ago. Basic and diluted LPS was DKK 0.02 compared to basic and diluted loss per share of DKK 0.02 a year ago. Cash flow used in operating activities was DKK 37,205,000 compared to cash used in operating activities of DKK 33,577,000 a year ago. Purchase of property, plant and equipment was DKK 272,000. For the six months, the company reported revenue of DKK 9,576,000 compared to DKK 24,412,000 a year ago. Operating loss was DKK 82,379,000 against DKK 58,017,000 a year ago. Loss before tax was DKK 69,052,000 compared to DKK 56,112,000 a year ago. Net result for the period was DKK 66,094,000 compared to DKK 53,123,000 a year ago. Basic and diluted LPS was DKK 0.04 compared to DKK 0.03 a year ago. Cash flow used in operating activities was DKK 93,698,000 compared to DKK 67,126,000 a year ago. Purchase of property, plant and equipment was DKK 272,000 compared to DKK 117,000 a year ago. The full year outlook for 2015 is improved. The company now expects a net loss in the range of DKK 155 million - DKK 185 million. The improvement is driven by the granted Orphan Drug status which entitles Veloxis to a waiver of the FDA prescription drug user fees for Envarsus® XR, along with overall cost savings.

Veloxis Pharmaceuticals A/S, Q2 2015 Earnings Call, Aug 27, 2015

Veloxis Pharmaceuticals A/S, Q2 2015 Earnings Call, Aug 27, 2015

U.S. Food and Drug Administration Grants Orphan Drug Status to Veloxis Pharmaceuticals's Envarsus® XR for Kidney Transplant Rejection Prophylaxis

Veloxis Pharmaceuticals A/S announced that Envarsus® XR was granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for prophylaxis of organ rejection in patients who convert from immediate-release tacrolimus. Envarsus® XR received marketing authorization from the FDA on July 10, 2015. Orphan drug designation is designed is to encourage the development of drugs that may provide significant benefit to patients suffering from rare diseases. The designation is granted by the FDA upon recognition that the prevalence of the U.S. target patient population is 200,000 patients or less. Orphan drug designation entitles Veloxis to a waiver of the FDA prescription drug user fees for Envarsus® XR as well as for potential tax incentives. Additionally, U.S. data exclusivity protection may be extended for up to seven years.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VELO:DC kr1.04 DKK 0.00

VELO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abzena PLC 71.00 GBp 0.00
Durect Corp $2.10 USD +0.08
Enzon Pharmaceuticals Inc $1.05 USD -0.01
Onxeo SA €3.93 EUR -0.08
Oxford Biomedica PLC 8.15 GBp +0.15
View Industry Companies
 

Industry Analysis

VELO

Industry Average

Valuation VELO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 16.0x
Price/Book 9.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VELOXIS PHARMACEUTICALS A/S, please visit www.veloxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.